TransMedics Group (NASDAQ:TMDX) Stock Rating Lowered by Zacks Investment Research

TransMedics Group (NASDAQ:TMDX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts. “

TMDX has been the subject of a number of other reports. Morgan Stanley assumed coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They set an “equal weight” rating for the company. Cowen assumed coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They set an “outperform” rating and a $40.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They set an “overweight” rating and a $34.00 price objective for the company. Finally, Canaccord Genuity assumed coverage on shares of TransMedics Group in a research note on Tuesday, May 28th. They set a “buy” rating and a $37.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $37.00.

NASDAQ TMDX traded up $0.01 on Thursday, reaching $21.80. The company had a trading volume of 172 shares, compared to its average volume of 92,236. The company has a current ratio of 7.55, a quick ratio of 6.82 and a debt-to-equity ratio of 0.48. TransMedics Group has a 1-year low of $19.76 and a 1-year high of $31.54. The stock’s fifty day moving average price is $23.85.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, June 12th. The company reported ($4.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($4.05). The company had revenue of $4.68 million for the quarter, compared to analysts’ expectations of $4.43 million. Equities research analysts forecast that TransMedics Group will post -1.95 EPS for the current year.

Hedge funds have recently modified their holdings of the company. Roubaix Capital LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $4,962,000. Janus Henderson Group PLC acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $15,059,000. Emerald Advisers LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $6,132,000. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $5,697,000. Finally, Lisanti Capital Growth LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $1,063,000. 49.17% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Further Reading: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on TransMedics Group (TMDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.